AstraZeneca PLC
AZNHealthcareNASDAQDrug Manufacturers - General · Last scanned Oct 24, 2026
Scan Results
Daily timeframeAstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The $265.96B market capitalization puts AZN squarely in mega-cap range for its industry. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
Market Cap
$265.96B
Beta
0.21
P/E (TTM)
25.63
P/E (Fwd)
15.12
EPS (TTM)
$6.69
EPS (Fwd)
$11.34
ROE
22.0%
ROA
8.2%
Cash
$4.97B
Total Debt
$32.35B
Free CF
$5.12B
52W Change
2.9%
Annual Financials
Cash vs Debt
Where AZN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AZN finished 7.13% below its 150-day moving average ($176.53) and 9.18% below its 200-day moving average ($180.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AZN overbought or oversold?
At the October 20, 2026 close, AZN's RSI(14) was 49.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
AstraZeneca PLC carries $32.35B in total debt against $4.97B in cash reserves — debt is roughly 6.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $5.12B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 22.0%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $44.35B (2022) to $58.74B (2025), reflecting a 32% increase over the period.
AZN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing AZN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.